Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017, 161(1):68-74 | DOI: 10.5507/bp.2017.003

Clinical correlates of B-type natriuretic peptide monitoring in outpatients with left ventricular assist device

Marketa Hegarovaa, Milos Kubaneka, Ivan Netukab, Jiri Malyb, Zora Dorazilovaa, Tomas Gazdicb, Janka Franekovac, Vera Lanskad, Vojtech Melenovskya, Josef Kautznera, Ivan Maleka
a Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
b Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
c Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
d Department of Biostatistics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Background: B-type natriuretic peptide (BNP) is a strong predictor of prognosis in chronic heart failure. We aimed to evaluate the clinical correlates and interpretation of BNP monitoring in LVAD out-patient recipients.

Methods: We performed a prospective study in 136 individuals after HeartMate II LVAD implantation. During follow-up they were divided into group A (severe adverse events requiring hospitalisation), group B (mild to moderate adverse events) and group C (an uneventful course). BNP was measured pre-implant, at the first out-patient visit, and then every 2 months. We identified the lowest level, and the level at the clinical event and/or the highest value in patients without clinical events (BNP peak).

Results: During a median follow-up of 298 days, 8 patients (6%) died, 21 patients (15%) experienced a severe adverse event (group A) and 38 patients (28%) had other adverse event (group B). Both the absolute value of BNP peak and its percentage values relative to pre-implant, first visit and minimum BNP had similar areas under the curve (AUC) to identify individuals with adverse events (group A and B) from group C. The performance of BNP peak rose from detection of infection to diagnosis of heart failure and culminated in individuals with pump thrombosis (AUC 0.68 vs. 0.75 vs. 0.93).

Conclusions: Serial measurement of BNP in outpatients with LVAD correlates with the occurrence of adverse events. Assessment of absolute values of BNP peak seems to have a similar accuracy to analysis of intra-individual variation of BNP and it is more practical.

Keywords: prognosis, B-type natriuretic peptide, ventricular assist devices, advanced heart failure

Received: January 25, 2017; Accepted: February 17, 2017; Prepublished online: February 27, 2017; Published: March 27, 2017  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Hegarova, M., Kubanek, M., Netuka, I., Maly, J., Dorazilova, Z., Gazdic, T., ... Malek, I. (2017). Clinical correlates of B-type natriuretic peptide monitoring in outpatients with left ventricular assist device. Biomedical papers, 161(1), 68-74. doi: 10.5507/bp.2017.003
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kirklin JK, Naftel DC, Pagani FD, Kormos, RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: 15,000 patients and counting Seventh INTERMACS. J Heart Lung Transplant 2015;34:1495-1504. Go to original source... Go to PubMed...
    2. McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD, Allen LA. Clinical outcomes following continuous-flow left ventricular assist device: a systematic review. Circ Heart Fail 2014;7:1003-13. Go to original source... Go to PubMed...
    3. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocrine Rev 2003; 24(3):341-56. Go to original source... Go to PubMed...
    4. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J 2000;51(2):151-63. Go to original source... Go to PubMed...
    5. Maisel AS, Krishnaswamy P, Νowak R, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. Ν Engl J Med 2002;347:161-7. Go to original source... Go to PubMed...
    6. Jannuzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-pro BNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J 2006;27:330-7. Go to original source... Go to PubMed...
    7. Bettencourt P, Frioes F, Azevedo A, Dias P, Pimenta J, Rocha-Goncalves F, Ferreira A. Prognostic information provided by serial measurement of brain natriuretic peptide in heart failure. Int J Cardiol 2004;93:45-8. Go to original source... Go to PubMed...
    8. Kubánek M, Goode K, Lánská V, Clark AL, Cleland JGF. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2009;11:367-77. Go to original source... Go to PubMed...
    9. Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O'Connor CM, Felker GM, Hernandez AF. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 2011;4:628-36. Go to original source... Go to PubMed...
    10. Knebel F, Schimke I, Pliet K, Schattke S, Martin S, Borges AC, Baumann G. ΝT-proBΝP in acute heart failure: Correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005;11(5):S38-S41. Go to original source... Go to PubMed...
    11. de Jonge N, van Wichen DF, Schipper ME, Lahpor JR, Gmelig-Meyling FHJ, Robles de Medina EO, de Weger RA. Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol 2002;39:963-9. Go to original source... Go to PubMed...
    12. Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg 1999;68:734-41. Go to original source... Go to PubMed...
    13. Sodian R, Loebe M, Schmitt C, Potapov EV, Siniawski H, Müller J, Hausmann H, Zurbruegg HR, Weng Y, Hetzer R. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol 2001;38:1942-9. Go to original source... Go to PubMed...
    14. Milting H, El Banayosy A, Kassner A, Fey O, Sarnowski P, Arusoglu L, Thieleczek R, Brinkmann T, Kleesiek K, Körfer R. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. J Heart Lung Transplant 2001;20:949-55. Go to original source... Go to PubMed...
    15. Kemperman H, van den Berg M, Kirkels H, de Jonge N. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem 2004;50:1670-2. Go to original source... Go to PubMed...
    16. Bruggink AH, de Jonge N, van Oosterhout MFM, Van Wichen DF, de Koning E, Lahpor JR, Kemperman H, Gmelig-Meyling FHJ, de Weger RA. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant 2006;25:174-80. Go to original source... Go to PubMed...
    17. Wohlschlaeger J, von Winterfeld M, Milting H, El Banayosy A, Schmitz KJ, Takeda A, Takeda N, Azhari P, Schmid C, August C, Schmid KW, Baba HA. Decreased myocardial chromogranin A expression and colocalization with brain natriuretic peptide during reverse cardiac remodeling after ventricular unloading. J Heart Lung Transplant 2008;27:442-9. Go to original source... Go to PubMed...
    18. Sato T, Seguchi O, Iwashima Y, Yanase M , Nakajima S, Hieda M, Watanabe T, Sunami H, Murata Y, Hata H, Fujita T, Kobayashi J, Nakatani. Serum brain natriuretic peptide concentration 60 days after surgery as a predictor of long-term prognosis in patients implanted with a left ventricular assist device. ASAIO Journal 2015;61:373-8. Go to original source... Go to PubMed...
    19. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. Go to original source... Go to PubMed...
    20. Mehra MR, Stewart GC, Uber PA. The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant 2014;33:1-11. Go to original source... Go to PubMed...
    21. Goldstein DJ, John R, Salerno C, Silvestry S, Moazami N, Horstmanshof D, Adamson R, Boyle A, Zucker M, Rogers J, Russell S, Long J, Pagani F, Jorde U. Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant 2013;32:667-70. Go to original source... Go to PubMed...
    22. Uriel N, Morrison KA, Garan AG, Kato TS, Yuzefpolskaya M, Latif F, Restaino SW, Mancini DM, Flannery M, Takayama H, John R, Colombo PC, Naka Y, Jorde UP. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices. J Am Coll Cardiol 2012;60:1764-75. Go to original source... Go to PubMed...
    23. Uriel N, Han J, Morrison KA, Nahumi N, Yuzefpolskaya M, Garan AR, Duong J, Colombo PC, Takayama, H, Thomas S, Naka Y, Jorde UP. Device thrombosis in Heart Mate II continuous-flow left ventricular assist devices: A multifactorial phenomenon. J Heart Lung Transplant 2014;33:51-9. Go to original source... Go to PubMed...
    24. Habib FM, Springal DR, Davies DJ, Oakley CM, Polak J M, Yacoub MH. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347:1151-5. Go to original source... Go to PubMed...
    25. Holman WL, Kirklin JK, Naftel DC, Kormos RL, Desvign-Nickens P, Camacho MT, Ascheim DD. Infection after implantation of pulsatile mechanical circulatory support device. J Thorac Cardiovasc Surg 2010;139:1632-6. Go to original source... Go to PubMed...
    26. Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Körfer R, Klein M, Krahn T, Kruska L, l Banayosy AE, Kramer F. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008;27:589-96. Go to original source... Go to PubMed...

    Return to the content